Introduction
Adenovirus vectors (Ad) have been developed for a wide range of potential gene therapy applications, including cystic fibrosis (CF). CF is caused by a mutation in the gene CF transmembrane conductance regulator (Cftr), and is considered a candidate for gene replacement therapy. Morbidity and mortality in CF patients is mainly due to persistent and progressive inflammation and infection in the lung. 1 Although accessible, the airway epithelium has evolved sophisticated mechanical, innate and adaptive immune defenses against foreign materials, including viruses. 2 Gene delivery is further complicated by the fact that airway epithelial cells turn over every few months. 3 As a result, effective gene therapy for CF may require repeat administration.
The advantages of Ad include ease of production, their ability to transduce non-dividing cells and a large cloning capacity. Disadvantages include host innate (inflammatory) and adaptive immune responses, both cellular and humoral. The adaptive immune response limits the efficacy of repeated delivery of Ad. 4 Helperdependent (HD) Ad was developed in an attempt to diminish the adaptive immune response. 5 Unlike earliergeneration Ad, which express adenovirus genes at a low level in the host, HD-Ad have all adenovirus coding regions deleted. As a result, the adaptive cytotoxic T-cell response is reduced in comparison to first-generation (FG) Ad when delivered systemically to mice. 6 The humoral response to systemic intravascular delivery of HD-Ad is similar to FG-Ad, 7 but a comparison in the lung has not previously been reported.
The capsid of HD-Ad and FG-Ad are presumably identical and can stimulate innate immunity and antibody formation. Systemic intravascular delivery of HDAd to mouse liver induced an acute inflammatory response similar to that of FG-Ad. 6 An acute inflammatory response to systemic HD-Ad was also reported in baboons. 8 However, changes in host cell gene expression caused by empty Ad capsid (which is conceptually similar to HD-Ad) were reduced compared to FG-Ad. 9 HD-Ad coat proteins can provide epitopes against which antibodies may develop. Systemic intravascular delivery of HD-Ad to mice resulted in neutralizing antibodies in serum that reduced the efficacy of a second administration. 10 However, a second administration to muscle, or intravascularly using very low doses of HD-Ad, appears to be feasible. 7, 11 In this study, we investigated the readministration of HD-Ad to the lungs of mice.
Results
To compare readministration of HD-Ad and FG-Ad to the lung we delivered several human serotype 5 Ad (see Materials and methods for abbreviated names) in various combinations (Figure 1 ) to mouse lungs by nasal aspiration. A first dose of 1.5 Â 10 10 particles or 5 Â 10 10 particles (designated 'high') of Ad was given. After 28 days we similarly delivered a second dose of 1.5 Â 10 10 particles of Ad not containing the same transgene as the first Ad (if any). After 3 days we killed the mice to examine transgene expression (b-galactosidase) in the lung and anti-Ad antibodies in bronchoalveolar lavage fluid (BALF) and serum. Initially, we performed a survey of transgene expression in the lung using X-gal stain to visualize b-galactosidase expression in small number of mice (Figure 2 ). Lungs from mice that received HD (without transgene) prior to HDlacZ (Figure 2b ) appeared similar in staining intensity and pattern to mice that had not received a first Ad (Figure 2a ). Mice that received the combination HDCftr-HDlacZ had somewhat less staining (Figure 2c ), while mice that received FG-HDlacZ ( Figure 2d ) were clearly lighter stained than the control group (Figure 2a ). To quantify these apparent differences we performed an experiment on a larger number of mice and homogenized the lungs to measure b-galactosidase activity ( Figure 3 ). Mice that received the combination HD-HDlacZ had slightly less activity than the control mice (none-HDlacZ), and mice that received the combination HDCftr-HDlacZ also had lower activity (Figure 3a) . Mice that received the combination FGHDlacZ had further reduced activity compared to the control group (Figure 3a) . Since immune responses to Ad are dose dependant, 7, 12, 13 we repeated the three above readministration combinations using the 'high' dose of the first virus (5 Â 10 10 particles). b-Galactosidase activity was reduced significantly compared to the control group, and was less than their regular dose counterparts, for all three high-dose readministrations (Figure 3a) . We then examined mice that received HDCftr or FG followed by FGlacZ (Figure 3b ). b-Galactosidase activity was significantly reduced compared to the control group ( Figure 3b ). We next compared the levels of anti-Ad antibodies in BALF and serum of the mice by ELISA (Figure 4 ). We used a pan-specific antibody that detects multiple mouse Ig isotypes. 14 The control group (none-HDlacZ) had very low antibody levels in BALF (Figure 4a ) and in serum (Figure 4b ). This was expected since the fluids were collected 3 days after delivery of the second Ad, which is not enough time to develop antibodies to a single administration of Ad. [15] [16] [17] All mice that received Ad readministration had significantly higher antibody levels compared to the control group in BALF ( Figure 4a ) and in serum (Figure 4b ). Mice that received the combination HD-HDlacZ had significantly lower antibody levels than mice that received FG-HDlacZ, in BALF ( Figure 4a ) and in serum (Figure 4b ). Antibody levels in the three highdose readministration groups were significantly greater than their regular dose counterparts in BALF (Figure 4a ). In serum antibody levels in the three high-dose readministration groups were significantly greater than their regular dose counterparts only for HD-high-HDlacZ (Figure 4b ), perhaps since serum antibody levels in the regular dose counterparts of HDCftr-high-HDlacZ and FG-high-HDlacZ were already relatively high. We then examined mice that received various combinations of HDCftr, FG and FGlacZ (Figure 4c and d) . Note that we added two groups in which we reversed the order in which the Ad were given. All mice that received Ad readministration had significantly higher antibody levels than the control group (none-FGlacZ) in BALF ( Figure  4c ) and in serum (Figure 4d ).
When we compared the b-galactosidase values for all groups in Figure 2 against the ELISA values in Figure 3 Next, we compared the levels of Ad-neutralizing antibodies in the BALF and serum of mice by measuring their ability to block infection of cultured cells by Ad ( Figure 6 ). Only in the control groups (none-none and none-HDlacZ), and in the group that received HDHDlacZ, were neutralizing antibodies not detected in any mice in BALF (Figure 6a ). Significantly elevated levels of neutralizing antibodies were found in the BALF of two of the three high-dose readministration groups (Figure 6a) . In serum, all readministration groups had significantly elevated levels of neutralizing antibodies (Figure 6b ). We then examined neutralizing antibodies in mice that received various combinations of HDCftr, FG and FGlacZ (Figure 6c and d) . Neutralizing antibodies were detected in BALF of some mice in all readministration groups (FGlacZ-FG was statistically significant, Figure 6c ). Neutralizing antibody concentrations in serum in all readministration groups were significantly elevated compared to the control group (Figure 6d ).
All Ad in this study were delivered in saline containing 0.1% LPC (see Materials and methods). This greatly enhances transduction of the cilated airway epithelium. 18, 19 We considered that LPC, a phospholipid, might interact with the virion coat proteins and inhibit antibody binding to the virus. We tested this hypothesis using the ELISA system described above and immune mouse BALF. We added solutions of LPC (from two sources), or L-a-phosphatidylcholine (PC), or SDS, to Adcoated ELISA plates at final lipid concentrations of 0-0.2%, then incubated with immune BALF (diluted 1:100). Only SDS disrupted the binding of Ad to anti-Ad antibodies in BALF (Supplementary Figure 1) . It is therefore unlikely that formulating Ad in 0.1% LPC for delivery to mice in our above studies interfered with antibody binding to Ad.
Discussion
In this study, we readministered combinations of HD-Ad and FG-Ad to mouse lung and examined transgene expression and antibody levels. We observed that all groups that received FG-Ad had generally lower transgene expression compared to control groups. These data are consistent with previous work examining readministration of FG-Ad to the lung. 15, 17, [20] [21] [22] [23] [24] [25] [26] [27] Transgene expression was only slightly lower when HD-Ad without a transgene was followed by HD-Ad with the transgene (b-galactosidase). When HD-Ad was delivered at a higher dose, however, b-galactosidase expression was reduced significantly in all groups (see below). We realize that measurements of transgene activity are influenced by multiple factors, including humoral and cellular responses to b-galactosidase, and that intermouse variation can be high. 15, 24, 28 Interestingly though, comparing the b-galactosidase and ELISA data for all groups revealed a negative correlation between bgalactosidase activity and anti-Ad antibody levels in BALF and serum. This suggests that anti-Ad antibodies were involved in determining the efficacy of Ad readministration as measured by b-galactosidase activity.
The group that first received HD-Ad without a transgene (HD-HDlacZ) had ELISA antibody levels in BALF and serum that were greater than the control group (none-HDlacZ), but were significantly less than the group that first received an FG-Ad. The HD-HDlacZ group also had no detectable neutralizing antibodies in BALF and very little in serum. These data indicate a reduced antibody response to HD-Ad compared to FGAd in the lung. First administration of the HD-Adexpressing VSV-G-epitope-tagged human Cftr (HDCftr) resulted in somewhat higher antibody levels than HDAd without a transgene. This result is consistent with studies that described host anti-Ad responses against Ad expressing foreign genes, including non-self transgenes as well as Ad genes. 15, [20] [21] [22] 24, 26 Although the adaptive cytotoxic T-cell response to HD-Ad is lower than FG-Ad when delivered systemically to mice, 6 the innate and humoral responses are similar.
6,7 However, Chirmule et al. 12 found that neutra- 
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lizing antibodies in mice and monkeys were lower for second-generation Ad vectors (DE1DE4) than for FG-Ad delivered to the lung. In the present study, we found lower antibody levels in BALF and serum for HD-Ad than for FG-Ad delivered to mouse lung. Therefore, unlike systemic intravascular delivery, differences between humoral responses to earlier and later generation Ad are apparent when Ad is delivered to the lung. This could be due to differences in immune surveillance and response between the systemic immunity and local immunity in the lung. Previous studies found that increasing the dose of Ad (FG or HD) increased the magnitude of the resulting cellular and humoral responses. 7, 12, 13 Some studies report Ad dose as virus particle number and many older studies report plaque-forming units (which is very difficult to estimate for HD-Ad). Rarely are both values reported, making direct dose comparisons difficult. We first chose a dose of 1. particles. The differences we observed between first administration of HD-Ad or FG-Ad at 1.5 Â 10 10 particles disappeared at 5 Â 10 10 particles, suggesting less advantage of HD-Ad over FG-Ad at higher doses. These data illustrate the importance of using the minimum dose necessary to achieve a therapeutic level of transgene expression (7) and the importance of achieving efficient Ad delivery to the airways. 19 It is interesting to note that studies of CF patients and Cftr knockout mice indicate that a low level of Cftr expression (5-10% of normal) is associated with less severe disease, 29, 30 and may therefore suffice for gene therapy.
For airway gene delivery using HD-Ad vectors, epithelium-specific promoters, such as the human cytokeratin 18 promoter, 41 should have advantage over ubiquitious promomters in therapeutic gene expression since they will not express therapeutic genes in antigenpresenting cells, therefore reducing the host immune responses against the therapeutic gene products. To further avoid host immune responses, our future experiments will be directed to examine the level and duration of transgene expression as well as the antibody response following readministration using various doses of viral vectors to determine the optimal virus dose. We will also determine the optimal intervals for readministration needed to provide a therapeutic level of gene expression. In addition, we will determine the number of repeated applications that can be applied without a significant loss of transduction and transgene expression.
The development of immunity to earlier-generation Ad delivered to the lung has been observed in rodents and non-human primates, 12, 17, 20, 23, 31 and antibody titers decreased over time. 17, 32, 33 In human trials with FG-Ad only low levels of neutralizing antibodies were found in BALF and serum [34] [35] [36] even after three broncho-spray administrations were given at 3-month intervals to CF patients. 37, 38 Mucosal immunity in the human lung may not be as long lived, in general, as systemic immunity. 39 Using an efficient delivery vehicle such as HD-Ad formulated in 0.1% LPC, 19 with an expression cassette capable of driving transgene expression for an extended period of time, 40, 41 it might be possible to readminister a moderate and potentially therapeutic dose of HD-Ad to the airways. CF patients could be monitored to ensure that mucosal immunity to Ad has declined before the vector is readministered. The success of this strategy might be improved by Ad serotype rotation 10, 42, 43 to maximize the length of time between readministration of Ad of the same serotype, and to avoid pre-existing immunity to serotypes common in human populations. 44, 45 Ad PEGylation, particularly using rotating methods, 27 and/or temporary modulation of the host's immune system, 17, 23, 33, 46, 47 might further increase the number of possible administrations.
Materials and methods

Adenovirus vectors
Five Ad vectors used in this study were HD (an empty HD-Ad, C4HSU), 48 HDlacZ (HD-Ad-expressing LacZ from the K18 promoter), 41 HDCftr (HD-Ad-expressing the human CFTR from the K18 promoter), 40 FG (FG Ad, H14), 48 FGlacZ (FG Ad-expressing LacZ from the CMV promoter). 41 FG-Ad (DE1) were grown by serial passage in 293 cells and were purified by CsCl density gradient centrifugation as previously described. 49 HD-Ad were grown by serial passage in 116 cells with AdNG163 helper virus and were purified by CsCl density gradient centrifugation as previously described. 50 HD-Ad preparations were determined by Southern blot to contain o0.05% helper virus contamination. Ad particle numbers were calculated by absorbance at 260 nm.
Ad delivery to mice
Female C57Bl/6 mice 8-10 weeks of age (Charles River Laboratories, Wilmington, MA, USA) were briefly anesthetised by methoxyflurane inhalation. In all 20 ml of Ad solution, consisting of 1.5 Â 10 10 or 5 Â 10 10 virus particles in 0.1% L-a-lysophosphatidylcholine (LPC; Sigma-Aldrich, USA) in 0.9% NaCl, was placed in small drops on the nares, from which it was aspirated into the lungs. After 28 days a second Ad solution (1.5 Â 10 10 virus particles in 0.1% LPC) was similarly delivered. Mice that received 'none' were given vehicle only (0.1% LPC). After 3 days the mice were killed and blood was collected by cardiac puncture. Bronchoalveolar lavage (BAL) was performed using 0.9 ml phosphate-buffered saline (instilled and recovered three times), and the lungs were placed in b-galactosidase buffer (see below) and homogenized. Samples were centrifuged to remove cells and debris and the supernatants were numbered and stored at À801C.
b-galactosidase assay
Mouse lungs, including trachea and airways, were homogenized in 2 ml ice-cold buffer consisting of 100 mM K-phosphate pH 7.8, 0.2% Triton X-100, 1 mM dithiothreitol and 1 Â proteinase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). Homogenate was cleared by centrifugation at 41C and the supernatant was stored at À801C. Thawed samples were incubated at 481C for 50 min to inactivate endogenous enzymes. Samples were cleared by centrifugation and assayed for b-galactosidase activity using a chemiluminescence kit (Galacto-Light, Applied Biosystems, Foster City, CA, USA) and a microplate luminometer (E.G.&G. Berthold LB96V, Bad Wildbad, Germany). Values, expressed as relative light units, were normalized for total protein content. Alternatively, mouse lungs were fixed, stained with X-gal, and cleared for photography as previously described. 41 
ELISA for anti-Ad antibodies
A pan-specific (IgA, IgE, IgGs, IgM) ELISA for mouse anti-human Ad5 antibodies was performed as previously described, 14, 27 except that tris-buffered saline (TBS) was used throughout instead of phosphate-buffered saline. A total of 96-well ELISA plates (Corning Costar, Acton, MA, USA) were coated overnight at 41C with 5 Â 10 10 particles of human Ad5 per well in 100 mM bicarbonate buffer pH 9.6. The plates were then washed 4 Â with TBS-T (TBS with 0.05% Tween-20) and blocked for 3 h at room temperature with 3% BSA in TBS. Mouse BALF diluted 1:100, or serum diluted 1:2000 in TBS, was added to the wells for overnight incubation at 41C. The plates The plates were washed 4 Â with TBS-T and then incubated with avidin-alkaline phosphatase (SigmaAldrich, USA), diluted 1:50 000 in TBS, for 2 h at room temperature. The plates were washed 4 Â with TBS-T, incubated with 1 mg/ml p-nitrophenyl phosphate (SigmaAldrich, USA) in 100 mM diethanolamine buffer pH 9.8, containing 0.5 mM MgCl 2 , for 10 min at room temperature. The reaction was stopped by the addition of EDTA (40 mM final), and optical density was read at 405 nm.
Assay for Ad neutralizing antibodies
The ability of mouse BALF or heat-inactivated serum (561C for 30 min) to block Ad5 infection of HeLa cells was measured as described previously. 12, 20 Two-fold serial dilutions of BALF, starting at 1 in 3, or serum, starting at 1 in 12, were incubated with 5 Â 10 9 virus particles of HD-Ad-K18lacZ 41 in a-MEM for 1 h at 371C. This mixture was then placed on B90% confluent HeLa cells for1 h at 371C. After 1 h an equal volume of a-MEM containing 20% fetal bovine serum was added. After 4 h this mixture was removed and replaced with a-MEM containing 10% fetal bovine serum. After 3 days the cells were fixed and stained with X-gal. The highest dilution that resulted in a minimum 50% reduction in blue cells was recorded. When no reduction was observed the lowest dilution was conservatively assigned.
Statistical analysis
A non-parametric approach was used for all comparisons since values of b-galactosidase and ELISA results generally exhibited non-normality and variance heterogeneity, and neutralizing antibody titer values were discrete. The NPAR1WAY Procedure (SAS/STAT User's Guide, Version 8) provided an overall analysis of rank values (Kruskal-Wallis test) for multiple experimental conditions (significance defined at Po0.05). Bonferroniadjusted P-values (0.05/number of comparisons) were used to assess significance of pair-wise comparisons (Wilcoxon-Mann-Whitney test) of specific experimental conditions. This approach is more conservative, but more robust, than a parametric analysis of variance and pairwise t-tests. The 'none-none' ELISA and neutralizing antibody values in Figures 4 and 6 are background controls shown for the sake of completeness, and were excluded from the statistical analysis.
